Cancer Institute at St Francis Hosptial

East Hills, New York 11548

0 studies enrolling now · 1 studies all time

What they study most

Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Studies at this site

• Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation — Withdrawn before enrolling